Hubert MD - Krystal Biotech Senior Development
| KRYS Stock | USD 161.76 4.82 3.07% |
Executive
Hubert MD is Senior Development of Krystal Biotech
| Age | 55 |
| Address | 2100 Wharton Street, Pittsburgh, PA, United States, 15203 |
| Phone | 412 586 5830 |
| Web | https://www.krystalbio.com |
Krystal Biotech Management Efficiency
The company has return on total asset (ROA) of (0.0883) % which means that it has lost $0.0883 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0168 %, meaning that it created $0.0168 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Krystal Biotech's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.13) in 2024. At this time, Krystal Biotech's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 630.6 M in 2024, whereas Other Assets are likely to drop slightly above 354 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeffrey Eisele | Apellis Pharmaceuticals | 62 | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| Daniel Martin | Deciphera Pharmaceuticals LLC | 49 | |
| Margarida Duarte | Deciphera Pharmaceuticals LLC | N/A | |
| Jennifer Larson | Deciphera Pharmaceuticals LLC | N/A | |
| Christine Sheehy | MeiraGTx Holdings PLC | 56 | |
| Matthew MD | Deciphera Pharmaceuticals LLC | 68 | |
| Jennifer Lee | Rhythm Pharmaceuticals | 48 | |
| Ram PharmD | Regenxbio | 47 | |
| Pr MD | Apellis Pharmaceuticals | N/A | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
| Yann Mazabraud | Rhythm Pharmaceuticals | 51 | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Olivier Danos | Regenxbio | 66 | |
| Jeffrey JD | Deciphera Pharmaceuticals LLC | N/A | |
| Alastair Leighton | MeiraGTx Holdings PLC | N/A | |
| Sarah Ryan | Rhythm Pharmaceuticals | N/A | |
| JD Esq | Apellis Pharmaceuticals | 51 | |
| Stephen MD | Regenxbio | 55 | |
| Tim Randall | MeiraGTx Holdings PLC | N/A | |
Management Performance
| Return On Equity | 0.0168 | ||||
| Return On Asset | -0.0883 |
Krystal Biotech Leadership Team
Elected by the shareholders, the Krystal Biotech's board of directors comprises two types of representatives: Krystal Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Krystal. The board's role is to monitor Krystal Biotech's management team and ensure that shareholders' interests are well served. Krystal Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Krystal Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Wilson, Head Marketing | ||
| David Chien, Senior Development | ||
| Hubert MD, Senior Development | ||
| Gloria Lin, Accounting Mang | ||
| Kathryn Romano, Executive Officer | ||
| Katherine Tuminello, HR Mang | ||
| Suma Krishnan, President Founder | ||
| Jennifer McDonough, Analytics Access | ||
| MS MBA, Chairman, Founder | ||
| John Karakkal, Vice Marketing | ||
| Ram Kamineni, Senior Operations | ||
| David Glynn, Commercial Counsel | ||
| John Thomas, General Secretary | ||
| Laurent Goux, Senior Europe | ||
| Andreas Orth, Ex Officer | ||
| Josh Suskin, Director Operations | ||
| Meg Dodge, Vice Communications |
Krystal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Krystal Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0168 | ||||
| Return On Asset | -0.0883 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 4.03 B | ||||
| Shares Outstanding | 28.56 M | ||||
| Shares Owned By Insiders | 12.77 % | ||||
| Shares Owned By Institutions | 92.37 % | ||||
| Number Of Shares Shorted | 2.45 M | ||||
| Price To Earning | (6.36) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Krystal Stock analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Krystal Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.39 | Revenue Per Share 1.867 | Return On Assets (0.09) | Return On Equity 0.0168 |
The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.